EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications

Mehrdad Javidi, Gregory E Alexander, Teddy Kosoglou, An Vermeulen iD, Anna Beutler, Tasneam Shagroni, Chandni Valiathan

CPT: Pharmacometrics & Systems Pharmacology · 2026-05 · 15 (5)

DOI: 10.1002/psp4.70207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 05.05.2026. Verfasst von Mehrdad Javidi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, San Diego, California, USA. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis, Meta-Analysis as Topic, Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson, Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Model‐based meta‐analysis (MBMA) offers a powerful framework for quantitatively integrating clinical trial data to inform drug development and decision‐making. In this study, a novel quantitative modeling approach using MBMA was proposed to project key efficacies of treatment in future Phase 2 or Phase 3 studies for an untested indication. As a case example, aggregate level data from a total of 67 published randomized‐controlled clinical trials were analyzed to build dose–response and longitudinal models, enabling us to bridge efficacy endpoints across psoriasis (PsO) and psoriatic arthritis (PsA), two related conditions within the psoriatic disease spectrum. The models incorporated both placebo and treatment effects while accounting for trial‐level heterogeneity, such as differences in study phase and population. Specifically, modeling has been done in two steps: (1) bridging across PsO and PsA indications and (2) bridging across endpoints within the PsA indication. Multiple model evaluations and assessments including external validation, by leaving one study out, were conducted to ensure robustness and confirm the predictive accuracy of the framework. Outcomes supported the potential of the proposed approach not only to characterize treatment effects across diseases but also to support evidence‐based decisions on trial design for the new indication. This approach holds strong promises for accelerating development timelines and improving success rates in drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticPsoriasisMeta-Analysis as TopicDrug DevelopmentHumansRandomized Controlled Trials as TopicEndpoint DeterminationClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

ACR20ACR50ACR70PASI75clinical trial designcross‐indication bridgingmodel‐based meta‐analysispsoriasispsoriatic arthritis

Autor:innen und Institutionen

  • Johnson & Johnson, San Diego, California, USA.
  • Johnson & Johnson, Spring House, Pennsylvania, USA.
  • Johnson & Johnson, Beerse, Belgium.

ORCID-Profile: An Vermeulen

Förderung

  • Johnson & Johnson
  • Johnson and Johnson

Zitieren

APA

Javidi, M., Alexander, G. E., Kosoglou, T., Vermeulen, A., Beutler, A., Shagroni, T., & Valiathan, C. (2026). MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications. CPT: Pharmacometrics & Systems Pharmacology, 15(5). https://doi.org/10.1002/psp4.70207

Vancouver

Javidi M, Alexander GE, Kosoglou T, Vermeulen A, Beutler A, Shagroni T, et al. MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(5). doi:10.1002/psp4.70207

BibTeX
@article{Javidi2026,
  author = {Javidi, Mehrdad and Alexander, Gregory E and Kosoglou, Teddy and Vermeulen, An and Beutler, Anna and Shagroni, Tasneam and Valiathan, Chandni},
  title = {MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/psp4.70207}
}
Kostenlos starten →